Provista Diagnostics is focused on developing world-class diagnostics for indications in breast and gynecological cancers. When used in combination with stand of care, Provista's blood-based diagnostic tests provide real-time actionable results to improve the accuracy of cancer detection.
Read More
Provista’s proprietary ProteoMark® Technology combines multiple Serum Protein Biomarkers and Tumor Associated Autoantibodies, with patient clinical data, to yield highly accurate diagnostic tests for women’s cancers.
Read More
Provista is developing a robust pipeline of diagnostic blood tests to address unmet needs in women’s cancers including breast, ovarian, endometrial and HPV-associated cancers.
Read More
Diagnostic Dilemma
Dense breast tissue is normal and common among woman and it refers to the appearance of breast tissue on a mammogram. Dense tissue appears white on a mammogram similar to both benign and cancerous lumps leading to both false negative and false positive results.
Read More


Sign Up for E-News
November 18, 2015

Nov 18, 2015

Provista Diagnostics to Present at the 2015 Canaccord Genuity Medical Technology & Diagnostics Forum NEW YORK, NY – November 18, 2015 – Provista Diagnostics, Inc., today announces that David Reese, Ph.D., President and Chief Executive Officer, will deliver a corporate overview at the upcoming Canaccord Genuity Medical Technology & Diagnostics […]
September 29, 2015

Sep 29, 2015

Provista Diagnostics Offers Hope for the Early Detection of Breast Cancer in Women with Dense Breasts   NEW YORK, NY – September 29, 2015:  Provista Diagnostics, Inc. today announced that the data from two prospective, randomized, multi-center clinical studies, evaluating a novel blood-based combinatorial protein biomarker assay, received overwhelming support from […]
September 23, 2015

Sep 23, 2015

Provista Diagnostics Announces announced that two posters highlighting new clinical data will be presented at the 2015 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium taking place September 25 – 27, 2015 in San Francisco, California. NEW YORK, NY – September 23, 2015:  Provista Diagnostics, Inc., a privately-held molecular diagnostics […]